Print

ESMO: New Agent Active in Advanced Ovarian Cancer, Dana-Farber Cancer Institute Study  
10/15/2010 6:40:33 AM

MedPageToday -- MILAN -- A quarter of patients with platinum-refractory or resistant ovarian cancer had a good response to an investigational agent that targets a kinase implicated in oncogenesis and tumor progression, results from a small preliminary clinical trial showed.
//-->